Chylothorax Treatment Planning

Variant: 1 Adult or child. Chylothorax: traumatic or iatrogenic etiology. Pretreatment planning.

Procedure	Appropriateness Category	Relative Radiation Level
Lymphangiography chest abdomen pelvis	Usually Appropriate	☢☢☢
Lymphangiography chest and abdomen	Usually Appropriate	☢☢☢
MR lymphangiography chest abdomen pelvis	Usually Appropriate	O
MR lymphangiography chest and abdomen	Usually Appropriate	O
Radiography chest	May Be Appropriate	☢
Radiography chest abdomen pelvis	May Be Appropriate	☢☢☢
MRI chest without and with IV contrast	May Be Appropriate	O
MRI chest without IV contrast	May Be Appropriate	O
Lymphoscintigraphy chest abdomen pelvis	May Be Appropriate	☢☢
Lymphoscintigraphy chest and abdomen	May Be Appropriate	☢☢
CT chest with IV contrast	May Be Appropriate	☢☢☢
CT chest without and with IV contrast	May Be Appropriate	☢☢☢
CT chest without IV contrast	May Be Appropriate	☢☢☢
CT chest abdomen pelvis with IV contrast	May Be Appropriate	☢☢☢☢
CT chest abdomen pelvis without and with IV contrast	May Be Appropriate	☢☢☢☢
CT chest abdomen pelvis without IV contrast	May Be Appropriate	☢☢☢☢
US chest	Usually Not Appropriate	O
US chest abdomen pelvis	Usually Not Appropriate	O

Variant: 2 Adult or child. Chylothorax: nontraumatic or unknown etiology. Pretreatment planning.

Procedure	Appropriateness Category	Relative Radiation Level
Lymphangiography chest abdomen pelvis	Usually Appropriate	☢☢☢
Lymphangiography chest and abdomen	Usually Appropriate	☢☢☢
MR lymphangiography chest abdomen pelvis	Usually Appropriate	O
MR lymphangiography chest and abdomen	Usually Appropriate	O
Radiography chest	May Be Appropriate	☢
Radiography chest abdomen pelvis	May Be Appropriate	☢☢☢
MRI chest without and with IV contrast	May Be Appropriate	O
MRI chest without IV contrast	May Be Appropriate	O
Lymphoscintigraphy chest abdomen pelvis	May Be Appropriate	☢☢
Lymphoscintigraphy chest and abdomen	May Be Appropriate	☢☢
CT chest with IV contrast	May Be Appropriate	☢☢☢
CT chest without and with IV contrast	May Be Appropriate	☢☢☢
CT chest abdomen pelvis with IV contrast	May Be Appropriate	☢☢☢☢
CT chest abdomen pelvis without and with IV contrast	May Be Appropriate	☢☢☢☢
CT chest abdomen pelvis without IV contrast	May Be Appropriate	☢☢☢☢
US chest	Usually Not Appropriate	O
US chest abdomen pelvis	Usually Not Appropriate	O
CT chest without IV contrast	Usually Not Appropriate	☢☢☢

Panel Members

Nima Kokabi, MD^a; Howard Dabbous, MD^b; Minhaj S. Khaja, ^c; Joe B. Baker, MD^d; Anupama G. Brixey, MD^e; William F. Browne, MD^f; Benjamin N. Contrella, MD^g; Saadia A. Faiz, MD^h; Andrew J. Gunn, MDⁱ; A. Tuba Karagulle Kendi, MD^j; Nicole A. Keefe, MD^k; Philip A. Linden, MD^l; Harold Litt, MD, PhD^m; Aditya M. Sharma, MBBSⁿ; Kanupriya Vijay, MD, MBBS^o; David Wang, ^p; Bill S. Majdalany, ^q.

Summary of Literature Review

Introduction/Background

Special Imaging Considerations

Discussion of Procedures by Variant

Variant 1: Adult or child. Chylothorax: traumatic or iatrogenic etiology. Pretreatment planning.

Variant 1: Adult or child. Chylothorax: traumatic or iatrogenic etiology. Pretreatment planning.
A. CT Chest With IV Contrast

Variant 1: Adult or child. Chylothorax: traumatic or iatrogenic etiology. Pretreatment planning.
B. CT Chest Without and With IV Contrast

Variant 1: Adult or child. Chylothorax: traumatic or iatrogenic etiology. Pretreatment planning.
C. CT Chest Without IV Contrast

Variant 1: Adult or child. Chylothorax: traumatic or iatrogenic etiology. Pretreatment planning.
D. CT Chest Abdomen Pelvis With IV Contrast

Variant 1: Adult or child. Chylothorax: traumatic or iatrogenic etiology. Pretreatment planning.
E. CT Chest Abdomen Pelvis Without and With IV Contrast

Variant 1: Adult or child. Chylothorax: traumatic or iatrogenic etiology. Pretreatment planning.
F. CT Chest Abdomen Pelvis Without IV Contrast

Variant 1: Adult or child. Chylothorax: traumatic or iatrogenic etiology. Pretreatment planning.
G. Lymphangiography Chest and Abdomen

Variant 1: Adult or child. Chylothorax: traumatic or iatrogenic etiology. Pretreatment planning.
H. Lymphangiography Chest Abdomen Pelvis

Variant 1: Adult or child. Chylothorax: traumatic or iatrogenic etiology. Pretreatment planning.
I. Lymphoscintigraphy Chest and Abdomen

Variant 1: Adult or child. Chylothorax: traumatic or iatrogenic etiology. Pretreatment planning.
J. Lymphoscintigraphy Chest Abdomen Pelvis

Variant 1: Adult or child. Chylothorax: traumatic or iatrogenic etiology. Pretreatment planning.
K. MR Lymphangiography Chest and Abdomen

Variant 1: Adult or child. Chylothorax: traumatic or iatrogenic etiology. Pretreatment planning.
L. MR Lymphangiography Chest Abdomen Pelvis

Variant 1: Adult or child. Chylothorax: traumatic or iatrogenic etiology. Pretreatment planning.
M. MRI Chest Without and With IV Contrast

Variant 1: Adult or child. Chylothorax: traumatic or iatrogenic etiology. Pretreatment planning.
N. MRI Chest Without IV Contrast

Variant 1: Adult or child. Chylothorax: traumatic or iatrogenic etiology. Pretreatment planning.
O. Radiography Chest

Variant 1: Adult or child. Chylothorax: traumatic or iatrogenic etiology. Pretreatment planning.
P. Radiography Chest Abdomen Pelvis

Variant 1: Adult or child. Chylothorax: traumatic or iatrogenic etiology. Pretreatment planning.
Q. US Chest

Variant 1: Adult or child. Chylothorax: traumatic or iatrogenic etiology. Pretreatment planning.
R. US Chest Abdomen Pelvis

Variant 2: Adult or child. Chylothorax: nontraumatic or unknown etiology. Pretreatment planning.

Variant 2: Adult or child. Chylothorax: nontraumatic or unknown etiology. Pretreatment planning.
A. CT Chest With IV Contrast

Variant 2: Adult or child. Chylothorax: nontraumatic or unknown etiology. Pretreatment planning.
B. CT Chest Without and With IV Contrast

Variant 2: Adult or child. Chylothorax: nontraumatic or unknown etiology. Pretreatment planning.
C. CT Chest Without IV Contrast

Variant 2: Adult or child. Chylothorax: nontraumatic or unknown etiology. Pretreatment planning.
D. CT Chest Abdomen Pelvis With IV Contrast

Variant 2: Adult or child. Chylothorax: nontraumatic or unknown etiology. Pretreatment planning.
E. CT Chest Abdomen Pelvis Without and With IV Contrast

Variant 2: Adult or child. Chylothorax: nontraumatic or unknown etiology. Pretreatment planning.
F. CT Chest Abdomen Pelvis Without IV Contrast

Variant 2: Adult or child. Chylothorax: nontraumatic or unknown etiology. Pretreatment planning.
G. Lymphangiography Chest and Abdomen

Variant 2: Adult or child. Chylothorax: nontraumatic or unknown etiology. Pretreatment planning.
H. Lymphangiography Chest Abdomen Pelvis

Variant 2: Adult or child. Chylothorax: nontraumatic or unknown etiology. Pretreatment planning.
I. Lymphoscintigraphy Chest and Abdomen

Variant 2: Adult or child. Chylothorax: nontraumatic or unknown etiology. Pretreatment planning.
J. Lymphoscintigraphy Chest Abdomen Pelvis

Variant 2: Adult or child. Chylothorax: nontraumatic or unknown etiology. Pretreatment planning.
K. MR Lymphangiography Chest and Abdomen

Variant 2: Adult or child. Chylothorax: nontraumatic or unknown etiology. Pretreatment planning.
L. MR Lymphangiography Chest Abdomen Pelvis

Variant 2: Adult or child. Chylothorax: nontraumatic or unknown etiology. Pretreatment planning.
M. MRI Chest Without and With IV Contrast

Variant 2: Adult or child. Chylothorax: nontraumatic or unknown etiology. Pretreatment planning.
N. MRI Chest Without IV Contrast

Variant 2: Adult or child. Chylothorax: nontraumatic or unknown etiology. Pretreatment planning.
O. Radiography Chest

Variant 2: Adult or child. Chylothorax: nontraumatic or unknown etiology. Pretreatment planning.
P. Radiography Chest Abdomen Pelvis

Variant 2: Adult or child. Chylothorax: nontraumatic or unknown etiology. Pretreatment planning.
Q. US Chest

Variant 2: Adult or child. Chylothorax: nontraumatic or unknown etiology. Pretreatment planning.
R. US Chest Abdomen Pelvis

Summary of Highlights

Supporting Documents

The evidence table, literature search, and appendix for this topic are available at https://acsearch.acr.org/list. The appendix includes the strength of evidence assessment and the final rating round tabulations for each recommendation.

For additional information on the Appropriateness Criteria methodology and other supporting documents, please go to the ACR website at https://www.acr.org/Clinical-Resources/Clinical-Tools-and-Reference/Appropriateness-Criteria.

Gender Equality and Inclusivity Clause

The ACR acknowledges the limitations in applying inclusive language when citing research studies that predates the use of the current understanding of language inclusive of diversity in sex, intersex, gender, and gender-diverse people. The data variables regarding sex and gender used in the cited literature will not be changed. However, this guideline will use the terminology and definitions as proposed by the National Institutes of Health.

Appropriateness Category Names and Definitions

Appropriateness Category Name	Appropriateness Rating	Appropriateness Category Definition
Usually Appropriate	7, 8, or 9	The imaging procedure or treatment is indicated in the specified clinical scenarios at a favorable risk-benefit ratio for patients.
May Be Appropriate	4, 5, or 6	The imaging procedure or treatment may be indicated in the specified clinical scenarios as an alternative to imaging procedures or treatments with a more favorable risk-benefit ratio, or the risk-benefit ratio for patients is equivocal.
May Be Appropriate (Disagreement)	5	The individual ratings are too dispersed from the panel median. The different label provides transparency regarding the panel’s recommendation. “May be appropriate” is the rating category and a rating of 5 is assigned.
Usually Not Appropriate	1, 2, or 3	The imaging procedure or treatment is unlikely to be indicated in the specified clinical scenarios, or the risk-benefit ratio for patients is likely to be unfavorable.

Relative Radiation Level Information

Potential adverse health effects associated with radiation exposure are an important factor to consider when selecting the appropriate imaging procedure. Because there is a wide range of radiation exposures associated with different diagnostic procedures, a relative radiation level (RRL) indication has been included for each imaging examination. The RRLs are based on effective dose, which is a radiation dose quantity that is used to estimate population total radiation risk associated with an imaging procedure. Patients in the pediatric age group are at inherently higher risk from exposure, because of both organ sensitivity and longer life expectancy (relevant to the long latency that appears to accompany radiation exposure). For these reasons, the RRL dose estimate ranges for pediatric examinations are lower as compared with those specified for adults (see Table below). Additional information regarding radiation dose assessment for imaging examinations can be found in the ACR Appropriateness Criteria^® Radiation Dose Assessment Introduction document.

Relative Radiation Level Designations
Relative Radiation Level*	Adult Effective Dose Estimate Range	Pediatric Effective Dose Estimate Range
O	0 mSv	0 mSv
☢	<0.1 mSv	<0.03 mSv
☢☢	0.1-1 mSv	0.03-0.3 mSv
☢☢☢	1-10 mSv	0.3-3 mSv
☢☢☢☢	10-30 mSv	3-10 mSv
☢☢☢☢☢	30-100 mSv	10-30 mSv
*RRL assignments for some of the examinations cannot be made, because the actual patient doses in these procedures vary as a function of a number of factors (e.g., region of the body exposed to ionizing radiation, the imaging guidance that is used). The RRLs for these examinations are designated as “Varies.”

References

1.	Doerr CH, Allen MS, Nichols FC, 3rd, Ryu JH. Etiology of chylothorax in 203 patients. Mayo Clinic proceedings 2005;80:867-70.
2.	Maldonado F, Cartin-Ceba R, Hawkins FJ, Ryu JH. Medical and surgical management of chylothorax and associated outcomes. Am J Med Sci 2010;339:314-8.
3.	Maldonado F, Hawkins FJ, Daniels CE, Doerr CH, Decker PA, Ryu JH. Pleural fluid characteristics of chylothorax. Mayo Clin Proc 2009;84:129-33.
4.	Zurcher KS, Huynh KN, Khurana A, et al. Interventional Management of Acquired Lymphatic Disorders. [Review]. Radiographics. 42(6):1621-1637, 2022 10.Radiographics. 42(6):1621-1637, 2022 10.
5.	Itkin M, Kucharczuk JC, Kwak A, Trerotola SO, Kaiser LR. Nonoperative thoracic duct embolization for traumatic thoracic duct leak: experience in 109 patients. J Thorac Cardiovasc Surg 2010;139:584-89; discussion 89-90.
6.	Pamarthi V, Stecker MS, Schenker MP, et al. Thoracic duct embolization and disruption for treatment of chylous effusions: experience with 105 patients. Journal of Vascular & Interventional Radiology. 25(9):1398-404, 2014 Sep.J Vasc Interv Radiol. 25(9):1398-404, 2014 Sep.
7.	Gurevich A, Hur S, Singhal S, et al. Nontraumatic Chylothorax and Chylopericardium: Diagnosis and Treatment Using an Algorithmic Approach Based on Novel Lymphatic Imaging. Annals of the American Thoracic Society. 19(5):756-762, 2022 05.Ann Am Thorac Soc. 19(5):756-762, 2022 05.
8.	Boffa DJ, Sands MJ, Rice TW, et al. A critical evaluation of a percutaneous diagnostic and treatment strategy for chylothorax after thoracic surgery. Eur J Cardiothorac Surg 2008;33:435-9.
9.	Lyon S, Mott N, Koukounaras J, Shoobridge J, Hudson PV. Role of interventional radiology in the management of chylothorax: a review of the current management of high output chylothorax. Cardiovasc Intervent Radiol 2013;36:599-607.
10.	Platis IE, Nwogu CE. Chylothorax. Thorac Surg Clin 2006;16:209-14.
11.	Scorza LB, Goldstein BJ, Mahraj RP. Modern management of chylous leak following head and neck surgery: a discussion of percutaneous lymphangiography-guided cannulation and embolization of the thoracic duct. Otolaryngol Clin North Am 2008;41:1231-40, xi.
12.	DePew ZS, Iqbal S, Mullon JJ, Nichols FC, Maldonado F. The role for tunneled indwelling pleural catheters in patients with persistent benign chylothorax. Am J Med Sci 2013;346:349-52.
13.	Murphy MC, Newman BM, Rodgers BM. Pleuroperitoneal shunts in the management of persistent chylothorax. Ann Thorac Surg 1989;48:195-200.
14.	Faiz SA, Pathania P, Song J, et al. Indwelling Pleural Catheters for Patients with Hematologic Malignancies. A 14-Year, Single-Center Experience. Ann Am Thorac Soc 2017;14:976-85.
15.	Jimenez CA, Mhatre AD, Martinez CH, Eapen GA, Onn A, Morice RC. Use of an indwelling pleural catheter for the management of recurrent chylothorax in patients with cancer. Chest 2007;132:1584-90.
16.	Cope C. Diagnosis and treatment of postoperative chyle leakage via percutaneous transabdominal catheterization of the cisterna chyli: a preliminary study. J Vasc Interv Radiol 1998;9:727-34.
17.	Cope C, Salem R, Kaiser LR. Management of chylothorax by percutaneous catheterization and embolization of the thoracic duct: prospective trial. J Vasc Interv Radiol 1999;10:1248-54.
18.	Cope C, Kaiser LR. Management of unremitting chylothorax by percutaneous embolization and blockage of retroperitoneal lymphatic vessels in 42 patients. J Vasc Interv Radiol 2002;13:1139-48.
19.	Ushinsky A, Guevara CJ, Kim SK. Intranodal lymphangiography with thoracic duct embolization for the treatment of chyle leaks after head and neck cancer surgery. Head & Neck. 43(6):1823-1829, 2021 06.Head Neck. 43(6):1823-1829, 2021 06.
20.	Chen CS, Kim JW, Shin JH, et al. Lymphatic imaging and intervention for chylothorax following thoracic aortic surgery. Medicine. 99(34):e21725, 2020 Aug 21.Medicine (Baltimore). 99(34):e21725, 2020 Aug 21.
21.	Nadolski GJ, Itkin M. Lymphangiography and thoracic duct embolization following unsuccessful thoracic duct ligation: Imaging findings and outcomes. Journal of Thoracic & Cardiovascular Surgery. 156(2):838-843, 2018 08.J Thorac Cardiovasc Surg. 156(2):838-843, 2018 08.
22.	Majdalany BS, Saad WA, Chick JFB, Khaja MS, Cooper KJ, Srinivasa RN. Pediatric lymphangiography, thoracic duct embolization and thoracic duct disruption: a single-institution experience in 11 children with chylothorax. Pediatr Radiol. 48(2):235-240, 2018 02.
23.	Pan F, Richter GM, Do TD, et al. Treatment of Postoperative Lymphatic Leakage Applying Transpedal Lymphangiography - Experience in 355 Consecutive Patients. ROFO Fortschr Geb Rontgenstr Nuklearmed. 194(6):634-643, 2022 06.
24.	Binkert CA, Yucel EK, Davison BD, Sugarbaker DJ, Baum RA. Percutaneous treatment of high-output chylothorax with embolization or needle disruption technique. J Vasc Interv Radiol 2005;16:1257-62.
25.	Majdalany BS, Sanogo ML, Pabon-Ramos WM, et al. Complications during Lymphangiography and Lymphatic Interventions. [Review]. Seminars in Interventional Radiology. 37(3):309-317, 2020 Aug.SEMIN. INTERVENT. RADIOL.. 37(3):309-317, 2020 Aug.
26.	Laslett D, Trerotola SO, Itkin M. Delayed complications following technically successful thoracic duct embolization. J Vasc Interv Radiol 2012;23:76-9.
27.	Cholet C, Delalandre C, Monnier-Cholley L, Le Pimpec-Barthes F, El Mouhadi S, Arrive L. Nontraumatic Chylothorax: Nonenhanced MR Lymphography. [Review]. Radiographics. 40(6):1554-1573, 2020 Oct.
28.	Krishnamurthy R, Hernandez A, Kavuk S, Annam A, Pimpalwar S. Imaging the central conducting lymphatics: initial experience with dynamic MR lymphangiography. Radiology 2015;274:871-8.
29.	Liu NF, Lu Q, Jiang ZH, Wang CG, Zhou JG. Anatomic and functional evaluation of the lymphatics and lymph nodes in diagnosis of lymphatic circulation disorders with contrast magnetic resonance lymphangiography. J Vasc Surg 2009;49:980-7.
30.	Pieper CC, Feisst A, Schild HH. Contrast-enhanced Interstitial Transpedal MR Lymphangiography for Thoracic Chylous Effusions. Radiology. 295(2):458-466, 2020 05.
31.	Pimpalwar S, Chinnadurai P, Chau A, et al. Dynamic contrast enhanced magnetic resonance lymphangiography: Categorization of imaging findings and correlation with patient management. Eur J Radiol. 101:129-135, 2018 Apr.
32.	Savla JJ, Itkin M, Rossano JW, Dori Y. Post-Operative Chylothorax in Patients With Congenital Heart Disease. J Am Coll Cardiol. 69(19):2410-2422, 2017 May 16.
33.	Smith CL, Liu M, Saravanan M, et al. Liver lymphatic anatomy and role in systemic lymphatic disease. Eur Radiol. 32(1):112-121, 2022 Jan.
34.	Hayashi S, Miyazaki M. Thoracic duct: visualization at nonenhanced MR lymphography--initial experience. Radiology 1999;212:598-600.
35.	Erden A, Fitoz S, Yagmurlu B, Erden I. Abdominal confluence of lymph trunks: detectability and morphology on heavily T2-weighted images. AJR Am J Roentgenol 2005;184:35-40.
36.	Kato T, Takase K, Ichikawa H, Satomi S, Takahashi S. Thoracic duct visualization: combined use of multidetector-row computed tomography and magnetic resonance imaging. J Comput Assist Tomogr 2011;35:260-5.
37.	Matsushima S, Ichiba N, Hayashi D, Fukuda K. Nonenhanced magnetic resonance lymphoductography: visualization of lymphatic system of the trunk on 3-dimensional heavily T2-weighted image with 2-dimensional prospective acquisition and correction. J Comput Assist Tomogr 2007;31:299-302.
38.	Pinto PS, Sirlin CB, Andrade-Barreto OA, Brown MA, Mindelzun RE, Mattrey RF. Cisterna chyli at routine abdominal MR imaging: a normal anatomic structure in the retrocrural space. Radiographics 2004;24:809-17.
39.	Takahashi H, Kuboyama S, Abe H, Aoki T, Miyazaki M, Nakata H. Clinical feasibility of noncontrast-enhanced magnetic resonance lymphography of the thoracic duct. Chest 2003;124:2136-42.
40.	Hyun D, Lee HY, Cho JH, et al. Pragmatic role of noncontrast magnetic resonance lymphangiography in postoperative chylothorax or cervical chylous leakage as a diagnostic and preprocedural planning tool. European Radiology. 32(4):2149-2157, 2022 Apr.
41.	Kim EY, Hwang HS, Lee HY, et al. Anatomic and Functional Evaluation of Central Lymphatics With Noninvasive Magnetic Resonance Lymphangiography. Medicine. 95(12):e3109, 2016 Mar.
42.	Chen S, Tan X, Wu R, et al. Non-enhanced MR lymphography of the thoracic duct: improved visualization following ingestion of a high fat meal-initial experience. Clin Physiol Funct Imaging. 37(6):730-733, 2017 Nov.
43.	Jeon YJ, Cho JH, Hyun D, et al. Management of chyle leakage after general thoracic surgery: Impact of thoracic duct embolization. Thoracic Cancer. 12(9):1382-1386, 2021 05.
44.	Liu ME, Branstetter BFt, Whetstone J, Escott EJ. Normal CT appearance of the distal thoracic duct. AJR Am J Roentgenol 2006;187:1615-20.
45.	Smith TR, Grigoropoulos J. The cisterna chyli: incidence and characteristics on CT. Clin Imaging 2002;26:18-22.
46.	Kiyonaga M, Mori H, Matsumoto S, Yamada Y, Sai M, Okada F. Thoracic duct and cisterna chyli: evaluation with multidetector row CT. Br J Radiol. 85(1016):1052-8, 2012 Aug.
47.	Liu DY, Shao Y, Shi JX. Unilateral pedal lymphangiography with non-contrast computerized tomography is valuable in the location and treatment decision of idiopathic chylothorax. J Cardiothorac Surg 2014;9:8.
48.	Kos S, Haueisen H, Lachmund U, Roeren T. Lymphangiography: forgotten tool or rising star in the diagnosis and therapy of postoperative lymphatic vessel leakage. Cardiovasc Intervent Radiol 2007;30:968-73.
49.	Sachs PB, Zelch MG, Rice TW, Geisinger MA, Risius B, Lammert GK. Diagnosis and localization of laceration of the thoracic duct: usefulness of lymphangiography and CT. AJR Am J Roentgenol 1991;157:703-5.
50.	Alejandre-Lafont E, Krompiec C, Rau WS, Krombach GA. Effectiveness of therapeutic lymphography on lymphatic leakage. Acta Radiol 2011;52:305-11.
51.	Deso S, Ludwig B, Kabutey NK, Kim D, Guermazi A. Lymphangiography in the diagnosis and localization of various chyle leaks. Cardiovasc Intervent Radiol 2012;35:117-26.
52.	Matsumoto T, Yamagami T, Kato T, et al. The effectiveness of lymphangiography as a treatment method for various chyle leakages. Br J Radiol 2009;82:286-90.
53.	Ruan Z, Zhou Y, Wang S, Zhang J, Wang Y, Xu W. Clinical use of lymphangiography for intractable spontaneous chylothorax. Thorac Cardiovasc Surg 2011;59:430-5.
54.	Jardinet T, Veer HV, Nafteux P, Depypere L, Coosemans W, Maleux G. Intranodal Lymphangiography With High-Dose Ethiodized Oil Shows Efficient Results in Patients With Refractory, High-Output Postsurgical Chylothorax: A Retrospective Study. AJR. American Journal of Roentgenology. 217(2):433-438, 2021 08.AJR Am J Roentgenol. 217(2):433-438, 2021 08.
55.	Yannes M, Shin D, McCluskey K, Varma R, Santos E. Comparative Analysis of Intranodal Lymphangiography with Percutaneous Intervention for Postsurgical Chylous Effusions. Journal of Vascular & Interventional Radiology. 28(5):704-711, 2017 May.J Vasc Interv Radiol. 28(5):704-711, 2017 May.
56.	Bazancir LA, Jensen RJ, Frevert SC, Ryom P, Achiam MP. Embolization of the thoracic duct in patients with iatrogenic chylothorax. Diseases of the Esophagus. 34(9), 2021 Sep 09.Dis Esophagus. 34(9), 2021 Sep 09.
57.	Pui MH, Yueh TC. Lymphoscintigraphy in chyluria, chyloperitoneum and chylothorax. J Nucl Med 1998;39:1292-6.
58.	Takanami K, Ichikawa H, Fukuda H, Takahashi S. Three-dimensional lymphoscintigraphy using SPECT/CT and 123I-BMIPP for the preoperative detection of anatomical anomalies of the thoracic duct. Clin Nucl Med 2012;37:1047-51.
59.	Weiss M, Schwarz F, Wallmichrath J, et al. Chylothorax and chylous ascites. Clinical utility of planar scintigraphy and tomographic imaging with SPECT/CT. Nucl Med (Stuttg). 54(5):231-40, 2015.
60.	Yang J, Codreanu I, Zhuang H. Minimal lymphatic leakage in an infant with chylothorax detected by lymphoscintigraphy SPECT/CT. Pediatrics 2014;134:e606-10.
61.	Okuda I, Udagawa H, Hirata K, Nakajima Y. Depiction of the thoracic duct by magnetic resonance imaging: comparison between magnetic resonance imaging and the anatomical literature. Jpn J Radiol 2011;29:39-45.
62.	Okuda I, Udagawa H, Takahashi J, Yamase H, Kohno T, Nakajima Y. Magnetic resonance-thoracic ductography: imaging aid for thoracic surgery and thoracic duct depiction based on embryological considerations. Gen Thorac Cardiovasc Surg 2009;57:640-6.
63.	Yu DX, Ma XX, Wang Q, Zhang Y, Li CF. Morphological changes of the thoracic duct and accessory lymphatic channels in patients with chylothorax: detection with unenhanced magnetic resonance imaging. Eur Radiol 2013;23:702-11.
64.	Yu DX, Ma XX, Zhang XM, Wang Q, Li CF. Morphological features and clinical feasibility of thoracic duct: detection with nonenhanced magnetic resonance imaging at 3.0 T. J Magn Reson Imaging 2010;32:94-100.
65.	Kuetting D, Luetkens J, Fimmers R, Sprinkart AM, Attenberger U, Pieper CC. MRI Assessment of Chylous and Nonchylous Effusions: Use of Multipoint Dixon Fat Quantification. Radiology. 296(3):698-705, 2020 Sep.
66.	Amorosa JK, Bramwit MP, Mohammed TL, et al. ACR appropriateness criteria routine chest radiographs in intensive care unit patients. Journal of the American College of Radiology. 10(3):170-4, 2013 Mar.
67.	Bender B, Murthy V, Chamberlain RS. The changing management of chylothorax in the modern era. [Review]. European Journal of Cardio-Thoracic Surgery. 49(1):18-24, 2016 Jan.Eur J Cardiothorac Surg. 49(1):18-24, 2016 Jan.
68.	Eibenberger KL, Dock WI, Ammann ME, Dorffner R, Hormann MF, Grabenwoger F. Quantification of pleural effusions: sonography versus radiography. Radiology 1994;191:681-4.
69.	Nadolski GJ, Itkin M. Feasibility of ultrasound-guided intranodal lymphangiogram for thoracic duct embolization. J Vasc Interv Radiol 2012;23:613-6.
70.	Lee C, Colletti PM, Chung JH, et al. ACR Appropriateness Criteria® Acute Respiratory Illness in Immunocompromised Patients. J Am Coll Radiol 2019;16:S331-S39.
71.	Jokerst C, Chung JH, Ackman JB, et al. ACR Appropriateness Criteria® Acute Respiratory Illness in Immunocompetent Patients. J Am Coll Radiol 2018;15:S240-S51.
72.	Hooper C, Lee YC, Maskell N, BTS Pleural Guideline Group. Investigation of a unilateral pleural effusion in adults: British Thoracic Society Pleural Disease Guideline 2010. Thorax. 65 Suppl 2:ii4-17, 2010 Aug.
73.	Pinto E, Dori Y, Smith C, et al. Neonatal lymphatic flow disorders: impact of lymphatic imaging and interventions on outcomes. J Perinatol. 41(3):494-501, 2021 03.
74.	National Academies of Sciences, Engineering, and Medicine; Division of Behavioral and Social Sciences and Education; Committee on National Statistics; Committee on Measuring Sex, Gender Identity, and Sexual Orientation. Measuring Sex, Gender Identity, and Sexual Orientation. In: Becker T, Chin M, Bates N, eds. Measuring Sex, Gender Identity, and Sexual Orientation. Washington (DC): National Academies Press (US) Copyright 2022 by the National Academy of Sciences. All rights reserved.; 2022.
75.	American College of Radiology. ACR Appropriateness Criteria® Radiation Dose Assessment Introduction. Available at: https://edge.sitecorecloud.io/americancoldf5f-acrorgf92a-productioncb02-3650/media/ACR/Files/Clinical/Appropriateness-Criteria/ACR-Appropriateness-Criteria-Radiation-Dose-Assessment-Introduction.pdf.

Disclaimer

The ACR Committee on Appropriateness Criteria and its expert panels have developed criteria for determining appropriate imaging examinations for diagnosis and treatment of specified medical condition(s). These criteria are intended to guide radiologists, radiation oncologists and referring physicians in making decisions regarding radiologic imaging and treatment. Generally, the complexity and severity of a patient’s clinical condition should dictate the selection of appropriate imaging procedures or treatments. Only those examinations generally used for evaluation of the patient’s condition are ranked. Other imaging studies necessary to evaluate other co-existent diseases or other medical consequences of this condition are not considered in this document. The availability of equipment or personnel may influence the selection of appropriate imaging procedures or treatments. Imaging techniques classified as investigational by the FDA have not been considered in developing these criteria; however, study of new equipment and applications should be encouraged. The ultimate decision regarding the appropriateness of any specific radiologic examination or treatment must be made by the referring physician and radiologist in light of all the circumstances presented in an individual examination.